C. J. Edwards

849 total citations
18 papers, 544 citations indexed

About

C. J. Edwards is a scholar working on Rheumatology, Immunology and Molecular Biology. According to data from OpenAlex, C. J. Edwards has authored 18 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in C. J. Edwards's work include Rheumatoid Arthritis Research and Therapies (7 papers), Spondyloarthritis Studies and Treatments (5 papers) and Atherosclerosis and Cardiovascular Diseases (4 papers). C. J. Edwards is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Spondyloarthritis Studies and Treatments (5 papers) and Atherosclerosis and Cardiovascular Diseases (4 papers). C. J. Edwards collaborates with scholars based in United Kingdom, United States and Spain. C. J. Edwards's co-authors include Emma L. Williams, Humeira Badsha, T Y Lian, Cheng Lay Teh, H H Chng, Vernon T. Farewell, David D’Cruz, NJ McHugh, Ian N Bruce and Yasmeen Ahmad and has published in prestigious journals such as Annals of the Rheumatic Diseases, Osteoporosis International and Lara D. Veeken.

In The Last Decade

C. J. Edwards

17 papers receiving 521 citations

Peers

C. J. Edwards

RHEUM

IMMUN

PFM

HEMAT

ONCOL

A. Rahman United Kingdom

Michael P. Keith United States

S. Menon United Kingdom

Luis Alonso González Colombia

Natalia Soria Spain

Julie M. Robertson United States

Antonios Psarras United Kingdom

Kateryna Vostretsova Canada

EK Li China

R J Powell United Kingdom

A. Rahman United Kingdom

C. J. Edwards

510 ×1.2

RHEUM

306 ×1.2

IMMUN

71 ×1.0

PFM

72 ×1.0

HEMAT

41 ×0.6

ONCOL

Citations per year, relative to C. J. Edwards C. J. Edwards (= 1×) peers A. Rahman

Countries citing papers authored by C. J. Edwards

Since Specialization

Citations

This map shows the geographic impact of C. J. Edwards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. J. Edwards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. J. Edwards more than expected).

Fields of papers citing papers by C. J. Edwards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. J. Edwards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. J. Edwards. The network helps show where C. J. Edwards may publish in the future.

Co-authorship network of co-authors of C. J. Edwards

This figure shows the co-authorship network connecting the top 25 collaborators of C. J. Edwards. A scholar is included among the top collaborators of C. J. Edwards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. J. Edwards. C. J. Edwards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Onna, Marloes van, Sofía Ramiro, Mette Holland‐Fischer, et al.. (2020). THU0586 ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE. Annals of the Rheumatic Diseases. 79. 535–535.

Edwards, C. J., A. Kivitz, Paul Bird, et al.. (2016). THU0422 Apremilast Monotherapy as The First Systemic Treatment in DMARD-Naïve Patients with Active Psoriatic Arthritis: 3-Year Treatment Results. Annals of the Rheumatic Diseases. 75. 342–342. 1 indexed citations

Holroyd, Christopher, et al.. (2016). AB1115-HPR Dose Reduction of Biological Therapies in Rheumatoid Arthritis - The Patient's Perspective. Annals of the Rheumatic Diseases. 75. 1313–1313. 3 indexed citations

Gladman, Dafna D., Arthur Kavanaugh, Ade Adebajo, et al.. (2015). OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials. Annals of the Rheumatic Diseases. 74. 133–134. 7 indexed citations

Fong, Warren, et al.. (2015). FRI0195 ERAP1 Allotypes and Disease Severity in Ankylosing Spondylitis. Annals of the Rheumatic Diseases. 74. 495–495. 1 indexed citations

Edwards, C. J., Ade Adebajo, Alan Kivitz, et al.. (2015). SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4). Annals of the Rheumatic Diseases. 74. 863–864. 10 indexed citations

Kavanaugh, Arthur, Maurizio Cutolo, Dafna D. Gladman, et al.. (2014). OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. Annals of the Rheumatic Diseases. 73. 90–91. 8 indexed citations

Schett, Georg, Philip J. Mease, Dafna D. Gladman, et al.. (2014). AB0746 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. Annals of the Rheumatic Diseases. 73. 1050–1050. 4 indexed citations

Mease, Philip J., Arthur Kavanaugh, Ade Adebajo, et al.. (2013). SAT0299 Apremilast: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials in patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases. 72. A685–A685. 3 indexed citations

10.

Birbara, C., et al.. (2013). OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial. Annals of the Rheumatic Diseases. 72. A85–A86. 11 indexed citations

11.

Birbara, C., et al.. (2013). SAT0280 Efficacy of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis, Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial. Annals of the Rheumatic Diseases. 72. A678–A678. 2 indexed citations

12.

Williams, Emma L., C. J. Edwards, Cyrus Cooper, & Richard O. C. Oreffo. (2012). The osteoarthritic niche and modulation of skeletal stem cell function for regenerative medicine. Journal of Tissue Engineering and Regenerative Medicine. 7(8). 589–608. 3 indexed citations

13.

Yee, C-S, Vernon T. Farewell, David Isenberg, et al.. (2011). The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Lara D. Veeken. 50(5). 982–988. 148 indexed citations

14.

Edwards, C. J., et al.. (2010). The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporosis International. 21(8). 1287–1293. 60 indexed citations

15.

Williams, Emma L., et al.. (2009). Anti-TNF-induced lupus. Lara D. Veeken. 48(7). 716–720. 149 indexed citations

16.

Edwards, C. J., et al.. (2003). Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 12(9). 672–676. 98 indexed citations

17.

Edwards, C. J., R.G.G. Russell, & Tim D. Spector. (2001). Statins and Bone: Myth or Reality?. Calcified Tissue International. 69(2). 63–66. 22 indexed citations

18.

Edwards, C. J.. (2001). Lupus in Singapore. Lupus. 10(12). 889–891. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact